DeepTek: Revolutionizing Medical Imaging and Fighting Tuberculosis

Introduction

Established in the U.S. in 2017, DeepTek stands at the forefront of medical imaging AI startups, pioneering the successful integration of AI technology into clinical practice. With a mission to bridge the gap in the imaging sector, DeepTek's cutting-edge solutions powered by deep learning algorithms have garnered widespread acclaim for their tangible benefits to patients, hospitals, and radiologists alike. The organization has secured multiple regulatory clearances, including the prestigious US FDA Clearance, solidifying its position as a leader in the field. Currently serving over 500 hospitals across India, Singapore, Thailand, the Philippines, Nigeria, Kenya, and beyond, DeepTek impacts the lives of millions annually, earning the trust of prominent equity partners such as TATA Capital Healthcare Fund II and NTT DATA.

DeepTek's Fight Against Tuberculosis

Tuberculosis remains a significant global health concern, claiming millions of lives each year. Recognizing the urgent need for early detection to facilitate effective treatment, DeepTek has spearheaded initiatives to combat this deadly disease.

Genki: AI Powered Lung Health Screening Tool

In the battle against tuberculosis, DeepTek unveiled Genki, an AI-powered Lung Health Screening Tool designed to revolutionize the detection process. Genki addresses the critical need for swift and accurate diagnosis by leveraging US FDA-cleared AI technology.

Key Features of Genki

• ·      Fast and Accurate: It analyses chest X-rays within a minute, triaging individuals with suspected pathologies like TB, pneumonia, and nodules. This rapid analysis allows for quicker diagnosis and treatment initiation.

• ·      Ideal for Resource-Limited Settings: Genki works seamlessly with mobile X-ray vans and even handheld X-ray machines, making it perfect for remote areas with limited access to healthcare experts.

• ·      Increased Screening Throughput: Compared to traditional methods, Genki can screen significantly more people per day, maximizing screening efficiency.

• ·      Comprehensive Analysis: Beyond TB, Genki identifies 20 different chest abnormalities, offering a broader picture of lung health.

Impact and Validation

Independent evaluations by renowned organizations such as StopTB Partnership and Friends for International TB confirm Genki's effectiveness. Notably, in the Greater Chennai Corporation's (GCC's) TB Free initiative, Genki achieved 97% accuracy, comparable to human experts, and increased TB case detection by 25 times. This translates to a significant improvement, with Genki identifying 500 presumptive TB suspects per 100,000 people screened, compared to just 20 previously identified.

Empowering Underserved Communities

By combining ultra-portable X-ray devices with AI, Genki brings TB screening directly to underserved communities. This innovative solution has the potential to revolutionize TB detection efforts, leading to faster diagnoses, improved patient outcomes, and ultimately, saving lives. Genki can screen over 200 people per day in a camp, increasing throughput by six times compared to conventional methods. Moreover, the AI can provide instant results and triage patients suspected of having TB.

DeepTek's commitment to fighting TB extends to various regions, including prisons, construction sites, and schools across Indian states like Pondicherry, Gujarat, Himachal Pradesh, Maharashtra, and Haryana. Through these efforts, DeepTek is making significant strides in combating tuberculosis and enhancing public health on a global scale.

Reflecting on these developments - Dr. Amit Kharat, Co-Founder and CEO of DeepTek

"Unlike traditional methods, AI-based TB screening can be deployed on edge devices offline or in the cloud and synced with portable or handheld X-ray devices. This makes it ideal for regions with limited healthcare infrastructure. By introducing mass screening of the vulnerable population, AI has the potential to revolutionize TB detection. Solutions like Genki exemplify this potential by enabling faster diagnoses and expanding access to TB screening in underserved communities."

Mylab Discovery Solutions: Spearheading the Fight Against Tuberculosis

Mylab Discovery Solutions stands as a beacon in the Indian biotech landscape, specializing in Molecular, Serological, Immunology, and Imaging solutions. With a steadfast commitment to combating infectious and non-communicable diseases, Mylab is at the forefront of diagnostic innovation, empowering individuals to lead healthier lives.

Pioneering TB Solutions

Aligned with the Prime Minister's ambitious goal to eliminate TB from India by 2025, Mylab offers a comprehensive suite of solutions for TB screening, detection, and prevention. One notable advancement is the integration of Mylab's PathoDetect TM MTB RIF & INH Resistance Detection Kit into the National TB Elimination Programme's Ni-kshay portal. This kit enables rapid and accurate detection of multidrug-resistant TB (MDR-TB), providing critical insights for tailored treatment strategies. With its ability to identify resistance to key first-line drugs like Rifampicin (RIF) and Isoniazid (INH), this kit is pivotal in the fight against TB.

Revolutionary Diagnostic Tools

Mylab has also introduced the Cy-TB test from Serum-Mylab, a groundbreaking diagnostic tool for latent TB infection. This innovative test detects latent TB before it progresses to an active disease state, offering a cost-effective and accurate solution for TB screening, particularly in high-burden regions.

Additionally, Mylab has unveiled MyBeam, an AI-enabled portable X-Ray device designed to enhance TB screening capabilities. Collaborating with various agencies, Mylab has deployed over 110 chest X-ray devices across India, facilitating early detection and intervention for TB cases.

Empowering Communities, Saving Lives

Mylab's contributions extend beyond technological innovation. By providing cutting-edge diagnostic solutions and fostering strategic partnerships, Mylab is empowering communities and saving lives in the relentless battle against tuberculosis. With unwavering dedication and pioneering spirit, Mylab continues to drive progress towards a TB-free India and a healthier future for all.

Reflecting on these developments - Hasmukh Rawal, MD & Co-founder of Mylab Discovery Solutions, stated,



“Our commitment lies in providing a comprehensive suite of solutions for TB screening, detection, and prevention. From our indigenous Cy-TB test integrated into NTEP to the MTB RIF & INH Resistance Detection Kit and the AI-enabled portable X-Ray device, we are honoured to contribute to the Prime Minister’s initiative to eradicate TB by 2025.”

“At Mylab, we are dedicated to leveraging technology and innovation to address public health challenges like TB, and we remain steadfast in our mission to create a TB-free world. We thank all our partners and stakeholders for their support in this crucial endeavour”, he added.